Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL

Journal of Bone and Mineral Research

Volumn 24, Issue 2, 2009, Pages 182-195

  Kostenuik, Paul J ^a   Nguyen, Hung Q ^a   McCabe, James ^a   Warmington, Kelly S ^a   Kurahara, Carol ^a   Sun, Ning ^a   Chen, Ching ^a   Li, Luke ^a   Cattley, Russ C ^a   Van, Gwyneth ^a   Scully, Shelia ^a   Elliott, Robin ^a   Grisanti, Mario ^a   Morony, Sean ^a   Hong, Lin Tan ^a   Asuncion, Frank ^a   Li, Xiaodong ^a   Ominsky, Michael S ^a   Stolina, Marina ^a   Dwyer, Denise ^a   Dougall, William C ^b   Hawkins, Nessa ^a   Boyle, William J ^a,c   Simonet, William S ^a   Sullivan, John K ^c   more..

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c AnaptysBio Inc   (United States)

Author keywords

Bone resorption; Denosumab; Osteoclast; Osteoprotegerin; RANKL

Indexed keywords

CHIMERIC PROTEIN; DENOSUMAB; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT HUMAN OSTEOPROTEGERIN IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE DENSITY; BONE MASS; CANCELLOUS BONE; CELL ACTIVATION; CELL SURFACE; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; CORTICAL BONE; EXON; FEMALE; GENE; HYPERCALCEMIA; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; RANKL GENE; TRABECULAR BONE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BONE AND BONES; BONE DENSITY; BONE RESORPTION; GENE KNOCK-IN TECHNIQUES; HUMANS; HYPERCALCEMIA; MICE; MOLECULAR SEQUENCE DATA; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PHENOTYPE; PROTEIN BINDING; RANK LIGAND; X-RAY MICROTOMOGRAPHY;

EID: 58649113384     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081112     Document Type: Conference Paper

References (48)

1. Burgess T, Qian YX, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan C, Burgess T, Elliot R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
3. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448.
4. Simonet WS, Lacey DL, Dunstan C, Kelly M, Chang MS, Luthy R, Nhuyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
5. Hsu H, Lacey DL, Dunstan C, Solovyev I, Colombero A, Timms E, Tan HL, Elliot G, Kelley MJ, Sarosi I, Wang L, Xia X, Elliot R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545.
6. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400.
7. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliot R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik PJ, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571.
8. Stolina M, Adamu S, Ominsky MS, Dzamba BJ, Asuncion F, Geng Z, Middleton S, Brown H, Pretorius J, Schett G, Bolon B, Feige U, Zack D, Kostenuik PJ 2005 RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 20:1756-1765.
9. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ 2003 Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18:852-858.
10. Ross AB, Bateman TA, Kostenuik PJ, Ferguson VL, Lacey DL, Dunstan CR, Simske SJ 2001 The effects of osteoprotegerin on the mechanical properties of rat bone. J Mater Sci Mater Med 12:583-588.
11. Padagas J, Colloton M, Shalhoub V, Kostenuik PJ, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan HL, Dunstan C, Lacey D, Martin D 2006 The receptor activator of nuclear factor-κB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int 78:35-44.
12. Kim H, Morgan-Bagley S, Kostenuik PJ 2006 RANKL inhibition: A novel strategy to decrease femoral head deformity after ischemic necrosis. J Bone Miner Res 21:1946-1954.
13. Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE 2007 The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in intact cynomolgus monkeys. Osteoporos Int 18:1073-1082.
14. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR 2001 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360.
15. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ 2003 A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(3 Suppl):887-892.
16. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831.
17. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ 2006 A study of the biological receptor activator of nuclear factor-κB ligant inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228.
18. Kostenuik PJ 2005 Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625.
19. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML 2000 Temperature-sensitive differential affinity of TRAIL for its receptors: DR5 is the highest affinity receptor. J Biol Chem 275:23319-23325.
20. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, Ambrose C, Tschopp J, Schneider P 2006 Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281:13964- 13971.
21. Sedger LM, Glaccum MB, Schuh J, Kanaly ST, Williamson E, Kayagaki N, Yun T, Smolak P, Le T, Goodwin R, Gliniak B 2002 Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32:2246-2254.
22. Naumann U, Wick W, Beschorner R, Meyermann R, Weller M 2004 Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol 107:17-22.
23. Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ 2005 The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146:3235-3243.
24. Hi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54:78-86.
25. Samadfam R, Xia Q, Goltzman D 2007 Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55-63.
26. Atkinson J, Cranmer P, Saunders T, Niehaus M, Smith SY, Varela A, Ominsky MS, Cosenza ME, Kostenuik PJ 2005 AMG 162, a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res 20:S294.
27. Ominsky MS, Schroeder J, Smith SY, Farrell DJ, Atkinson JE, Kostenuik PJ 2007 Denosumab (AMG 162), a fully human RANKL antibody, improves cortical and cancellous bone mass and bone strength in ovariectomized cynomolgus monkeys. J Bone Miner Res 22:S23.
28. Ominsky MS, Schroeder J, Jolette J, Smith SY, Farrell DJ, Atkinson JE, Kostenuik PJ 2007 Decreased bone turnover and porosity are asssociated with improved bone strength in ovariectomized (OVX) cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. J Bone Miner Res 22:S126.
29. Lee H, Zahra D, Vogelzang A, Newton R, Thatcher J, Quan A, So T, Zwirener J, Roentgen F, Padkjaer SB, Mackay F, Whitfeld PL, Mackay CR 2006 Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monocloncal antibodies. Nat Biotechnol 24:1279-1284.
30. Green LL 1999 Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the faclie generation of therapeutic human monoclonal antibodies. J Immunol Methods 231:11-23.
31. Lonberg N 2005 Human antibodies from transgenic animals. Nat Biotechnol 23:1117-1125.
32. Xu J, Tan J, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH 2000 Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-κB ligand. J Bone Miner Res 15:2178-2186.
33. Kodaira K, Mizuno A, Yasuda H, Shima N, Murakami A, Ueda M, Higashio K 1999 Cloning and characterization of the gene encoding mouse osteoclast differentiation factor. Gene 230:121-127.
34. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH 2001 Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 108:971-979.
35. Kearns AE, Khosla S, Kostenuik PJ 2008 OPG and RANKL regulation of bone remodeling in health and disease. Endocr Rev 29:155-192.
36. Ominsky MS, Schroeder J, Smith SY, Farrell JP, Kostenuik PJ, Atkinson JE 2006 Denosumab (AMG 162, a fully human RANKL antibody) increases cortical and cancellous bone mass in aged ovariectomized cynomolgus monkeys. J Bone Miner Res 21:S72.
37. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP 1999 Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274:13613-13618.
38. Bouxsein ML, Myers KS, Shultz KL, Donahue LR, Rosen CJ, Beamer WG 2005 Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res 20:1085-1092.
39. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066.
40. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Stolina M, Kostenuik PJ, Erben RG 2007 RANKL inhibition by denosumab prevents cortical bone loss in a murine model of glucocorticoid-induced osteoporosis. J Bone Miner Res 22:S4.
41. Jin Q, Cirelli JA, Park CH, Sugai JV, Taba M, Kostenuik PJ, Giannobile WV 2007 RANKL inhibition via osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol 78:1300-1308.
42. Shalhoub V, Faust J, Boyle WJ, Dunstan C, Kelley MJ, Kaufman S, Scully S, van Auken M, Lacey DL 1999 Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem 72:251-261.
43. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki SI, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N 1998 Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 250:229-234.
44. McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG 2008 Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 43:653-662.
45. Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N 2003 Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441-5449.
46. Ominsky MS, Schroeder J, Jolette J, Smith SY, Farrell DJ, Atkinson JE, Kostenuik PJ 2007 Decreased bone turnover and porosity are asssociated with improved bone strength in ovariectomized (OVX) cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. J Bone Miner Res 22:S126.
47. Ulrich-Vinther M, Andreassen TT 2005 Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif Tissue Int 76:280-286.
48. Ferrari S, Pierroz D, Bonnet N, Dwyer D, Stolina M, Kostenuik PJ 2007 A comparison of denosumab and alendronate in combination with PTH in ovariectomized knockin mice expressing humanized RANKL. J Bone Miner Res 22:S37.